Brinzolamide

Structural formula
General
Non-proprietary name	Brinzolamide
other names	(4 R ) -4-Ethylamino-2- (3-methoxypropyl) -1,1-dioxo-3,4-dihydrothieno [ 4,5- e ] thiazine-6-sulfonamide; ( R ) -4-Ethylamino-2- (3-methoxypropyl) -1,1-dioxo-3,4-dihydrothieno [ 4,5- e ] thiazine-6-sulfonamide;
Molecular formula	C 12 H 21 N 3 O 5 S 3
External identifiers / databases
EC number	620-511-8
ECHA InfoCard	100.149.376
PubChem	68844
DrugBank	DB01194
Wikidata	Q411517
Drug information
ATC code	S01 EC04
Drug class	Carbonic anhydrase inhibitors
properties
Molar mass	383.51 g · mol -1
Physical state	firmly
Melting point	131 ° C
solubility	easily soluble in methanol and ethanol
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302
	P: 264-270-301 + 312 + 330-501
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Brinzolamide is a sulfur- and nitrogen- containing, heterocyclic chemical compound that is derived from thiophene . Due to its effectiveness as a carbonic anhydrase inhibitor , it is used as a medicinal substance in eye drops to lower intraocular pressure .

A structurally related and similarly acting drug is dorzolamide .

properties

Brinzolamide is a white powder that is insoluble in water, but dissolves very well in ethanol and methanol . The water-insoluble substance is administered in the form of an eye drop suspension.

Clinical studies

The efficacy of brinzolamide as a ready-to-use product Azopt was tested in clinical studies (in parallel with the similar dorzolamide) in patients with glaucoma and increased intraocular pressure (over 23 mmHg). The preparation was able to reduce the pressure by 17 to 22% in 1% dosage. The results with dorzolamide in a 2% dose were between 13 and 22% for a pressure reduction.

Side effects

After application to the eye, the active ingredient enters the systemic bloodstream. Very common to common side effects are: taste disturbances (bitter or unusual taste), headache, temporary blurred vision for a few seconds to a few minutes after the instillation, ocular irritation, ocular hyperemia (sensation of foreign bodies in the eye).

Trade names

Monopreparations

Azopt (D, A, CH); Brinzo-Vision (D, A), Brinzolamid AL (D)

Combination preparations

Azarga (D, A, CH)

Individual evidence

↑ ^a ^b ^c ^d Azopt patient information (PDF file; 81 kB), FDA .
↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of (4R) -4- (ethylamino) -2- (3-methoxypropyl) -1,1-dioxo-3,4-dihydrothieno [3,2-e] thiazine-6 is shown, which is derived from a self-classification by the distributor -sulfonamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on December 28, 2019.

↑ Entry on brinzolamide at TCI Europe, accessed on February 16, 2020.

↑ Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T: Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. , Adv Ther. 2014 Dec; 31 (12): 1213-27, PMID 25430900

↑ Technical information AZOPT 10 mg / ml eye drop suspension, as of July 2005.

[fda-1] Azopt patient information (PDF file; 81 kB), FDA .

[2] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of (4R) -4- (ethylamino) -2- (3-methoxypropyl) -1,1-dioxo-3,4-dihydrothieno [3,2-e] thiazine-6 is shown, which is derived from a self-classification by the distributor -sulfonamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on December 28, 2019.

[SigmaAldrich-3] Entry on brinzolamide at TCI Europe, accessed on February 16, 2020.

[4] Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T: Randomized trial of brinzolamide / brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. , Adv Ther. 2014 Dec; 31 (12): 1213-27, PMID 25430900

[5] Technical information AZOPT 10 mg / ml eye drop suspension, as of July 2005.